CDC advisors recommend Pfizer’s maternal RSV vaccine in 11-1 vote

The CDC’s vac­cine ad­vi­sors on Fri­day af­ter­noon vot­ed 11-1 to rec­om­mend Pfiz­er’s ma­ter­nal RSV vac­cine for preg­nant peo­ple at 32 to 36 weeks of ges­ta­tion to pre­vent RSV in their in­fants.

The rec­om­men­da­tion comes about a month af­ter the FDA grant­ed ap­proval to the RSV vac­cine, known as Abrys­vo, for the same group of preg­nant peo­ple.

Sev­er­al com­mit­tee mem­bers said that this rec­om­men­da­tion was com­pli­cat­ed by the fact that there will al­so be a mon­o­clon­al an­ti­body avail­able to give to in­fants to pro­tect against RSV this up­com­ing sea­son.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.